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ABSTRACT Iron deficiency is the most common and widespread nutritional disorder in the world, affecting millions of
people in both nonindustrialized and industrialized countries. We estimated the costs, effects, and cost-effectiveness of
iron supplementation and iron fortification interventions in 4 regions of the world. The effects on population health were
arrived at by using a population model designed to estimate the lifelong impact of iron supplementation or iron
fortification on individuals benefiting from such interventions. The population model took into consideration effective-
ness, patient adherence, and geographic coverage. Costs were based on primary data collection and on a review of the
literature. At 95% geographic coverage, iron supplementation has a larger impact on population health than iron
fortification. Iron supplementation would avert 12,500 disability adjusted life years (DALY) annually in the European
subregion, with very low rates of adult and child mortality, to almost 2.5 million DALYs in the African and Southeast Asian
subregions, with high rates of adult and child mortality. On the other hand, fortification is less costly than supplemen-
tation and appears to be more cost effective than iron supplementation, regardless of the geographic coverage of
fortification. We conclude that iron fortification is economically more attractive than iron supplementation. However,
spending the extra resources to implement iron supplementation is still a cost-effective option. The results should be
interpreted with caution, because evidence of intervention effectiveness predominantly relates to small-scale efficacy
trials, which may not reflect the actual effect under expected conditions. J. Nutr. 134: 2678–2684, 2004.
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According to the WHO, iron deficiency is the most common
nutritional disorder in the world. Iron deficiency and its anemia
affect3.5 billion people in the developing world, well over two
persons out of every three (1). Iron-deficiency anemia (IDA)3 is
associated with significantly poorer performance on psychomotor
and mental development scales and behavioral ratings in infants,
lower scores on cognitive function tests in preschool children,
lower scores in cognitive function tests and educational achieve-
ment tests in school-age children (2–4), and poor pregnancy
outcome (5). Furthermore, IDA is associated with low work
productivity in adults (6). Young children and pregnant and
postpartum women are most commonly and severely affected by
IDA because of the high iron demands of infant growth and
pregnancy. Mental retardation and maternal and perinatal mor-
tality are regarded as the most severe outcomes of IDA (7).
Current WHO and UNICEF guidelines recommend that
interventions for the prevention and the control of iron defi-
ciency should follow an integrated, long-term approach. IDA
must be addressed by a multidisciplinary approach, including
the following elements: 1) increased iron intake (i.e., iron-rich
diets, increasing iron absorption, and iron and folate supple-
ments, fortification of wheat flour and other complementary
foods with iron and other micronutrients, where appropriate);
2) infection control (i.e., public health measures to control
hookworm infections, malaria, and schistosomiasis); 3) im-
proved nutritional status (i.e., control of major nutrient defi-
ciencies, diet diversification, and infection prevention) (2,7).
There is clear evidence of the importance of investing in
nutritional interventions to reduce mortalities and morbidities
[e.g. (8,9)], and to reduce the economic impact of IDA. A
cost-of-illness study has shown that cognitive delays in children,
lower productivity among adults, and premature births as a result
of IDA may lead to significant productivity losses (10–14). Illus-
trative calculations for 10 developing countries by Horton and
Ross (14) suggest that the median value of annual physical
productivity losses due to iron deficiency is about US$0.32 per
capita, or 0.57% of the gross domestic product (GDP). The
benefit:cost ratio for long-term iron fortification programs would
range from 6:1 to 36:1, the latter including the discounted future
benefits attributable to cognitive improvements. Also, the Asian
Development Bank found its benefits, in terms of reduced lost
productivity, compare favorably with its costs (15).
1 A full list of subregions and included countries, as well as detailed cost
figures, are available with the online posting of this paper at www.nutrition.org.
2 To whom correspondence should be addressed.
E-mail: Baltussen@bmg.eur.nl.
3 Abbreviations used: AfrD: African subregion with very high rates of adult and
child mortality; CEA: cost-effectiveness analysis; DALY: disability adjusted life
year; GDP: gross domestic product; I$: international dollar; IDA: iron-deficiency
anemia; WHO-CHOICE: WHO—Choosing Interventions that are Cost Effective.
0022-3166/04 $8.00 © 2004 American Society for Nutritional Sciences.
Manuscript received 18 March 2004. Initial review completed 24 May 2004. Revision accepted 23 June 2004.
2678
 at Erasm
us R
otterdam
 42300.7802.430 / BIN 8025 on O
ctober 31, 2006 
jn.nutrition.org
D
ow
nloaded from
 
 http://jn.nutrition.org/cgi/content/full/134/10/2678/DC1
Supplemental Material can be found at: 
We examined the cost-effectiveness of iron fortification
and of iron supplementation in iron-deficiency control in four
subregions of the world; other public health measures are not
included in the analysis. Costs and effects were evaluated by
using a modeling approach, based upon primary data collec-
tion and a review of the literature. The analysis reported upon
in this paper is based on the impact of interventions to prevent
maternal and perinatal mortality only. The analysis of the
impact of interventions on intellectual and mental develop-
ment is beyond the scope of this paper.
We did not aim to express health benefits of iron-deficiency
control in monetary terms, thereby avoiding its many method-
ological pitfalls (16–17). Rather, we followed standard practice in
the economic evaluation of health programs by performing cost-
effectiveness analysis (CEA) and by expressing outcomes in
health gains, i.e., disability adjusted life years (DALY) averted
(16–18). This also facilitates a comparison of the economic
attractiveness of iron-deficiency control with other interventions,
e.g., subjected to analysis in the WHO-CHOICE (CHOosing
Interventions that are Cost Effective) program4 (18).
METHODS
Overview of cost-effectiveness analysis
CEA in health aims to inform policy makers and decision makers
on the economic attractiveness (or returns on investment) of inter-
ventions to reduce disease-related mortality and morbidity. By assess-
ing costs and effectiveness of an intervention, a “value for money”
estimate is provided. The cost-effectiveness of a given intervention is
typically expressed as costs per unit of effectiveness, with costs mea-
sured in monetary terms and effectiveness measured in health metrics
terms. Health metrics measure the impact of an intervention on the
quality of life (morbidity) and length of life (mortality) of a popula-
tion and express this as a single number such as a quality adjusted life
year (17) or DALY (19). Interventions with a favorable cost-effec-
tiveness ratio (e.g., low US$ per DALY) are said to be eligible for
implementation, at least in economic terms.
CEA can be undertaken in many ways, and there have been several
attempts to develop methodological guidelines to make results more
comparable. WHO has developed a standardized set of methods and
tools that can be used to analyze the societal costs and effectiveness of
current and possible new interventions simultaneously (18,20). The
WHO-CHOICE project is designed to provide regularly updated data-
bases on the costs and the effects of a full range of promotive, preventive,
curative, and rehabilitative health interventions.
Regions analyzed
Most countries do not have the capacity to evaluate all potential
interventions aimed at improving given health indicators at the national
and the subnational level, and global estimates are too general and of
little use to any specific country. However, countries may benefit from
regional evaluations of data, where data of neighboring countries with
similar settings are pooled. The present analysis drew on a comprehen-
sive examination of 14 world subregions defined by geographic proximity
and epidemiology according to WHO classification. This paper only
presents results for four regions selected on the basis of their diverse
epidemiological patterns. The four subregions are the African subregion
with high rates of adult and child mortality (AfrD), the South American
subregion with low adult and child mortality (AmrB), the European
subregion with low adult and very low child mortality (EURA), and the
Southeast Asian subregion with high rates of adult and child mortality
(SearD). A full list of subregions and included countries is available in
Supplemental Table 1. Full results for all regions are available at the
WHO Web site (21).
Iron supplementation and iron fortification
We estimated the cost-effectiveness of iron supplementation and
iron fortification programs, each at geographic coverage levels of 50,
80, and 95%.5
Iron supplementation. It is becoming increasingly clear that the
main target group for iron supplementation should be all women of
reproductive age, leading to adequate reserves for mother and fetus
during pregnancy (22). In this analysis, iron supplementation in-
volves the provision of iron to pregnant women during antenatal
visits. The assumed dose follows WHO guidelines, with daily supple-
mentation of 60 mg elemental iron given to pregnant women for 6
mo during pregnancy, and for 3 mo postpartum (22). The effective-
ness estimates of iron supplementation interventions as applied in our
analysis were based on a thorough review of the burden of disease
attributable to iron deficiency by Stoltzfus et al. (5) for the same 14
world subregions as applied in the analysis. For the epidemiological
subregion AfrD, for example, Stoltzfus et al. (5) reported that iron
deficiency contributes to 22% of all maternal mortality in women
between 30 and 44 y, and to 33% of all perinatal mortality. For the
purposes of this analysis, we therefore assumed that the maximum
attainable health effects in women between 30 and 44 y of any iron
supplementation intervention in subregion AfrD are an annual re-
duction of maternal mortality of 22% and of perinatal mortality of
33%. The effectiveness of iron supplementation intervention is re-
duced by the following: 1) the assumed suboptimal geographic cov-
erage level, i.e., not all pregnant women receive iron supplementa-
tion; and 2) noncompliance to the full iron supplement regimen.
Reasons for noncompliance with iron-deficiency treatment include
inadequate program support (such as lack of financial support), in-
sufficient service delivery (such as lack of supplies), and patient
factors (such as misunderstanding instructions, side effects, or frus-
tration about the frequency and the number of pills taken). Galloway
and McGuire (23) estimated that noncompliance reduces the number
of women with sufficient iron intake and therefore the maximum
attainable health effects of iron supplementation by 33%.
Iron fortification. Iron fortification involves the addition of iron,
usually with folic acid, to an appropriate food vehicle that is made
available to the population at large. Cereal flour is the most common
food vehicle but others, such as noodles, rice, and various sauces,
have also been used (7). The present CEA is based on the addition
of elemental iron powders to cereal flours. Elemental iron powders
have been used for this purpose for 50 y and continue to be the
most widely used iron compound (24). They have the advantage of
causing few, if any, color and flavor problems in stored food vehicles.
They are inexpensive and suitable for fortification of staple foods,
such as wheat flour and maize flour. The analysis is based on the use
of electrolytic iron (45 m, 325 mesh) of which evidence suggests
that it should be a useful iron fortificant (23).
There have been very few trials of either efficacy or effectiveness
of iron fortification for improving iron status. In industrialized coun-
tries with high bioavailability diets, this strategy has been assumed to
have a beneficial effect on iron status. In populations consuming low
bioavailability diets, such as those consumed in many developing
country contexts, there is some evidence of benefit, as reviewed by
Allen and Gillespie (25) and also suggested in recent studies (26–28).
However, the benefit may be much less, and much greater amounts of
fortification may have to be added (24). For that reason, the maxi-
mum attainable health effects of fortification were considered to be
4 WHO seeks to provide the evidence decision makers need to set priorities
and to improve the performance of their health systems. The Global Programme
on Evidence for Health Policy is assembling regional databases on the costs,
impact on population health, and cost-effectiveness of key health interventions.
This work, known as WHO-CHOICE, started in 1998 with the development of
standard tools and methods. The objectives of WHO-CHOICE are to develop a
standardized method for cost-effectiveness analysis that can be applied to all
interventions in different settings; to develop and disseminate tools required to
assess intervention costs and impacts at the population level; to determine the
costs and effectiveness of a wide range of health interventions, presented with
probabilistic uncertainty analysis; to summarize the results in regional databases
that will be available on the Internet; and to assist policy makers and other
stakeholders to interpret and use the evidence.
5 These coverage levels do not specifically relate to current or attainable
levels for iron-deficiency control, but are standardized in WHO-CHOICE analyses
to foster comparability between study results.
COST-EFFECTIVENESS OF IRON-DEFICIENCY INTERVENTIONS 2679
 at Erasm
us R
otterdam
 42300.7802.430 / BIN 8025 on O
ctober 31, 2006 
jn.nutrition.org
D
ow
nloaded from
 
only 50% of those of supplementation (personal communication, R.
Stoltzfus, Cornell University). As in iron supplementation, the effec-
tiveness of iron fortification at the population level was further
reduced for two reasons. Firstly, we explored the costs and effects in
the event that fortification reaches various suboptimal geographic
coverage levels. Second, within these coverage levels, only a limited
proportion of the population consumes the food vehicle in sufficient
quantities to absorb sufficient iron levels of the targeted population.
Estimating population health effects
The effects on population health were arrived at by using a
population model designed to estimate the lifelong impact of iron
supplementation or iron fortification on individuals benefiting from
such interventions. The model simulated the health of a population
over time and allows individuals to be categorized into one of the
following three mutually exclusive health states: pregnant, nonpreg-
nant, and dead. Depending on parameters, such as fertility, maternal
mortality, and perinatal mortality, individuals moved between these
states. In our analysis, the baseline scenario was of a population
devoid of any iron-deficiency control (20). In the intervention sce-
nario, a single intervention was introduced, reducing the maternal
and perinatal mortality rates and allowing the overall population
health to improve. Differences in population health estimates be-
tween the baseline and the intervention scenario were considered a
measure of intervention effectiveness, expressed in DALYs.
Baseline scenario. To establish the baseline scenario, population
health in the absence of any iron-deficiency control program needs to be
assessed. Therefore, the effects of any preexisting iron interventions
should be removed, thereby increasing the currently observed maternal
and perinatal mortality rates in each of the 14 global burden of disease
subregions (19). The increase was based on the assumed effectiveness of
iron supplementation programs (Table 1). In this scenario, we assumed
that no effective iron fortification intervention exists.
For example, in subregion AfrD, the current maternal mortality
rate for 30–44 y olds is 1210 per 100,000 live births, in the presence
of an iron supplementation program at an assumed geographic cov-
erage rate of 20% and an assumed adherence of 67% (23). In AfrD
region, an optimal iron-deficiency program would reduce maternal
mortality by 22%. The baseline maternal mortality rate, in the
absence of any iron-deficiency program, would then be 1240 per
100,000 live births.6 Baseline perinatal mortality rates were calcu-
lated in the same way. Population health in the baseline scenario was
then estimated by running the disease model with baseline maternal
and perinatal mortality rates.
Intervention scenarios. The present analysis provides estimates for
six different intervention scenarios: iron supplementation and iron for-
tification, separately, each at geographic coverage rates of 50, 80, and
95%. The introduction of iron supplementation and iron fortification
interventions decreases the baseline maternal and perinatal mortality
rates with the extent of reduction being equal to the effectiveness of the
interventions, as illustrated above (Table 1). In subregion AfrD, e.g., the
baseline maternal mortality rate is 1240 per 100,000 live births. As stated
above, an optimal iron supplementation program would reduce maternal
mortality with 22%. The intervention, with an assumed 67% adherence
(23), would lead to a maternal mortality rate of 1070 per 100,000 live
births.7 Intervention perinatal mortality rates were calculated in the
same way. Population health in the intervention scenario was then
estimated by running the disease model by using these intervention-
specific maternal and perinatal mortality rates.
Estimating costs
Costs of all interventions are reported in international dollars (I$)
to facilitate more meaningful comparisons across regions. The WHO
guide to cost-effectiveness analysis (18) provides more detail. The
base year is 2000.
Iron supplementation. Patient-level costs for iron supplementa-
tion include provision of iron to pregnant women during 4 antenatal
visits at the primary health care facility. For the women who currently
attend antenatal clinics, iron supplementation was assumed to add
only five additional min to the 15 min that antenatal visits last. In
other words, costs of 4  1/3 visit (1.33 visit) were included if iron
supplementation was evaluated at a coverage level equal to or smaller
than that of antenatal care in a certain region. Antenatal care
coverage was based on WHO estimates (Table 2). For the women
who do not currently attend antenatal clinics, the full 15 min of the
4 visits were included. In other words, for iron supplementation
6 Calculated as [0.0121  (1  20%  67%  22%)].
7 Calculated as [0.0124/(1  22%  5%  7%)].
TABLE 1
Calculation of maternal and perinatal mortality rates in baseline and intervention scenarios1
Baseline scenario Intervention scenario: iron supplementation at 95% coverage
Currently
observed
rate
Maximum
attainable
reduction
of
mortality2
Coverage
of current
program
Compliance
to current
program
Net impact
of current
program
Baseline
mortality rate
Maximum
attainable
reduction
of
mortality2 Coverage Compliance % Reduction
Intervention
mortality rate
(1) (2) (3) (4) (5)  (2)*(3)*(4) (6)  (1)*[1  (5)] (7) (8) (9) (10)  (7)*(8)*(9) (11)  (6)*[1  (10)]
% %
Maternal
mortality,
30–44 y
AfrD 0.0121 22 20 67 3 0.0124 22 95 67 14 0.0107
AmrB 0.0026 15 50 67 5 0.0027 15 95 67 10 0.0025
EurA 0.0000 10 80 67 6 0.0000 10 95 67 7 0.0000
SearD 0.0049 29 50 67 10 0.0053 29 95 67 19 0.0043
Perinatal
mortality
AfrD 0.0447 33 20 67 4 0.0466 33 95 67 21 0.0369
AmrB 0.0086 12 50 67 4 0.0089 12 95 67 7 0.0083
EurA 0.0019 8 80 67 4 0.0020 8 95 67 5 0.0019
SearD 0.0301 23 50 67 8 0.0325 23 95 67 15 0.0277
1 AfrD, African subregion with very high adult and high child mortality; AmrB, South American subregion with low adult and child mortality; EurA,
the European subregion with low adult and very low child mortality; SearD, Southeast Asian subregion with high rates of adult and child mortality.
2 In case of an optimal iron supplementation program, based on Stoltzfus et al. (5).
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coverage levels beyond that of antenatal care in a certain region, the
costs of 4 visits were included. Health facility unit cost estimates were
based on an econometric analysis of a large number of hospital
costing studies, reported in Adam et al. (29).
Costs of iron were estimated by following WHO guidelines on
iron supplementation interventions, with daily doses of 60 mg ele-
mental iron, for 6 mo during pregnancy, and for 3 mo postpartum
(21) (Table 1). Drugs prices for A regions were retrieved from a
Web-based drugstore (30); prices for other regions were retrieved
from the International Drug Price Indicator (31). All prices were
adjusted for regional transportation costs (32).
Iron supplementation interventions also use limited resource in-
puts at a level above that of the patient or the providing facility, for
employing program managers at the central administration at the
national level, for activities such as training, health nutrition educa-
tion, and supervision (Table 2). These are labeled program-level
costs. Estimated quantities of resources required to start up and then
to maintain each intervention for 10 y at national, provincial, and
district levels were based on a series of evaluations made by regional
costing teams in the different WHO subregions and validated against
the literature (categories of resource input included personnel, ma-
terials and supplies, media, transport, maintenance, utilities, and
capital). Details are available in Supplemental Table 2. Unit costs
estimates of program-level resource inputs, such as the salaries of
central administrators, capital costs of vehicles, storage costs, offices,
and furniture were obtained from a review of literature and were
supplemented by primary data from several countries [the full list of
unit cost estimates is available at the WHO Web site (21)]. The
process and the methodology to estimate program costs have been
described in detail in Johns et al. (32).
Iron fortification. Industry production costs of fortified flour were
based on estimates provided by the U.S. Agency for International
Development Micronutrient Program (33), including costs for scales,
dosifiers and electrolytic iron fortificant. Details are available in
Supplemental Table 3. The number of beneficiaries was estimated
using regional population sizes and assumptions on access to fortified
food (Table 3). Program costs at the national, provincial and districts
levels include management, legislation, health nutrition education
and supervision costs and were estimated in the same way as the iron
supplementation intervention. Details are available in Supplemental
Table 4. Average annual costs per beneficiary varied between I$0.06
and I$0.15 (Table 3).
When scaling-up iron supplementation and iron fortification inter-
ventions, the cost per beneficiary may decrease with increasing coverage
because of economies of scale (e.g., shared mass media costs at the
national level) or may increase because of diseconomies of scale (e.g.,
increased management costs per beneficiary in less populous remote
areas). The approach is described in detail in Johns et al. (32).
Uncertainty analysis
Estimates of the cost-effectiveness of interventions are subject to
uncertainty. This can be uncertainty related to the model structure or
uncertainty related to the exact values of the input data. Uncertainty
analysis in CEA has been developed as a tool to assess the impact of
uncertainty on study results and therefore study conclusions. In the
present study, uncertainty analysis were undertaken to consider how
uncertainty of epidemiological, effectiveness, and cost parameters
translates into uncertainty in the cost-effectiveness ratio. High and
low estimates of maternal and perinatal mortality were defined as
25% of the baseline values. Impacts of different interventions and
costs were also varied 25%.
RESULTS
The findings indicate that, in general, iron supplementa-
tion has a larger impact on population health than fortification
(Table 4). Iron supplementation would avert12,500 DALYs
per year in the European subregion and almost 2.5 million
DALYs in the African as well as in the Southeast Asian
subregion. On the other hand, fortification is less costly than
supplementation because it does not require a visit to a pro-
vider and the unit cost of supplementation increases sharply
with increasing coverage.
The Commission on Macroeconomics and Health recently
defined interventions that have a cost-effectiveness of less than
three times GDP per capita as cost effective (34). All 6 interven-
tions in the 4 regions are cost-effective according to this criterion.
The cost-effectiveness of fortification is always lower than the
cost-effectiveness of supplementation, regardless of the coverage
of fortification. Therefore, in terms of cost-effectiveness, fortifi-
TABLE 2
Annual costs of iron supplementation at 95% coverage (I$)1
Region
Patient level costs
Program
level
costs7
Patient and
program level
costs
Cost per
pregnant
women
Annual number of
pregnant women
receiving iron
supplementation3
Coverage
of
antenatal
care4
Cost per
outpatient
visit, at
95%
coverage5
Total
costs
outpatient
visits2
Costs of
drugs6
Cost per
recipient Total costs7
(1) (2) (3) (4) (5) (6)  (4)  (5) (7)  (1)*(6) (8) (9)  (7)  (8) (10)  (9)/(1)
% I$
AfrD 10,998,697 55 6.84 14.97 1.14 16.10 177,123,892 5,351,324 182,475,216 16.59
AmrB 8,623,181 71 9.90 19.88 0.90 20.78 179,193,221 5,241,404 184,434,625 21.39
EurA 4,068,145 95 25.13 33.09 12.96 46.04 187,309,461 16,766,683 204,076,144 50.16
SearD 31,597,515 57 3.85 9.25 0.87 10.12 319,741,462 9,448,557 329,190,020 10.42
1 AfrD, African subregion with very high adult and high child mortality; AmrB, South American subregion with low adult and child mortality; EurA,
the European subregion with low adult and very low child mortality; SearD, Southeast Asian subregion with high rates of adult and child mortality.
2 For coverage levels  coverage of antenatal care, 1.33 outpatient visit is included (4  1/3 visit); For coverage levels  coverage of antenatal
care, 4 full outpatient visit are included.
3 Equal to 95% of annual region specific number of life-births.
4 As percentage of women having at least one antenatal care visit during pregnancy.
5 Costs vary with coverage rate. For derivation, see Adam et al. (29).
6 See text for sources and derivation.
7 Costs figure is for single year. Costs vary over implementation period of 10 y and are discounted.
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cation should be the preferred option, especially in settings where
there are low levels of resource availability.
However, in scenarios where more resources were to become
available, the question of whether the extra resources should be spent
on achieving higher coverage levels merits exploration. To answer
this question, the extra costs and effects of implementing more costly
but also more effective interventions were compared and were sum-
marized in incremental cost-effectiveness ratios (Table 5). In all 4
regions, the overall pattern was similar. In settings of extreme re-
source constraints, iron fortification is the preferred option. The
incremental cost-effectiveness ratios for iron supplementation were
still below the criterion of 3  GDP, indicating that spending the
extra resources to implement iron supplementation is still a cost-
effective option, independent of coverage level.
Uncertainty analysis focusing on the impact of varying
assumptions about epidemiology, costs, and intervention ef-
TABLE 3
Annual costs of iron fortification at 95% coverage1
Region
Industry level costs
Program
level
costs2
Industry and
program level
costs
Cost per
beneficiaryTotal population
Access to
fortified food Beneficiaries
Industry level
cost per
beneficiary2 Total costs
(1) (2) (3)  (1)  (2) (4) (5)  (3)  (4) (6) (7)  (5)  (6) (8)  (7)/(3)
% I$
AfrD 334,580,563 60 190,710,921 0.009 1,684,893 23,203,578 24,888,471 0.13
AmrB 442,130,339 75 315,017,867 0.007 2,211,272 18,919,306 21,130,578 0.07
EurA 411,889,100 95 371,729,913 0.006 2,206,671 53,918,268 56,124,939 0.15
SearD 1,334,810,348 60 760,841,898 0.007 5,172,913 39,023,844 44,196,757 0.06
1 AfrD, African subregion with very high adult and high child mortality; AmrB, South American subregion with low adult and child mortality; EurA,
the European subregion with low adult and very low child mortality; SearD, Southeast Asian subregion with high rates of adult and child mortality.
2 See text for sources and derivation.
TABLE 4
Annualized costs, annual effects and average cost-effectiveness of iron deficiency control in 4 regions1
Intervention AfrD AmrB EurA SearD
Costs I$
Iron supplementation
50% $ 38,164,705 $ 63,385,379 $100,696,296 $ 91,685,848
80% $119,875,245 $116,771,583 $153,062,840 $214,686,470
95% $159,095,817 $165,492,669 $179,225,469 $286,217,588
Iron fortification
50% $ 15,464,385 $ 15,594,183 $ 35,273,367 $ 25,035,878
80% $ 19,192,967 $ 16,510,432 $ 41,649,470 $ 30,155,000
95% $ 21,867,282 $ 18,565,556 $ 49,311,983 $ 38,831,752
Effects DALYs averted
Iron supplementation
50% 1,274,974 130.202 6.569 1,311,084
80% 2,039,959 208.323 10.511 2,097,734
95% 2,422,451 247.383 12.482 2,491,059
Iron fortification
50% 570,884 72.874 4.657 587,052
80% 913,414 116.599 7.452 939,284
95% 1,084,680 138.461 8.849 1,115,400
Average cost-effectiveness I$ per DALY averted
Iron supplementation
50% $ 30 $ 487 $ 15,328 $ 70
80% $ 59 $ 561 $ 14,562 $ 102
95% $ 66 $ 669 $ 14,359 $ 115
Iron fortification
50% $ 27 $ 214 $ 7,574 $ 43
80% $ 21 $ 142 $ 5,589 $ 32
95% $ 20 $ 134 $ 5,573 $ 35
1 AfrD, African subregion with very high adult and high child mortality; AmrB, South American subregion with low adult and child mortality; EurA,
the European subregion with low adult and very low child mortality; SearD, Southeast Asian subregion with high rates of adult and child mortality.
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fectiveness revealed that the results were quite robust to vari-
ation in the model parameters within 25%. The mean cost-
effectiveness ratios for different strategies could, in some cases,
vary by a factor of almost 2 between the high and low esti-
mates. For example, in AfrD, if iron fortification is assumed
not to be 50% but 37.5% as effective as iron supplementation,
the cost-effectiveness of this intervention at 50% coverage
level changes from I$27 to I$36 per DALY averted. In case
iron fortification is assumed to be 62.5% as effective as iron
supplementation, the cost-effectiveness changes to I$21 per
DALY averted. However, the overall conclusion, that the
wide range of interventions examined here would have attrac-
tive cost-effective ratios, remained largely unchanged under
varying assumptions in the models.
DISCUSSION
The findings show that iron fortification has the lowest
cost-effectiveness ratio and is from the economic point of view
most attractive. However, one of the key processes in devel-
oping a fortification program is choosing a suitable food vehi-
cle. This can be a challenge, especially in countries with large
rural populations, with a small food industry with limited
technology, and with limited access to and low consumption
of processed foods. Moreover, consumption of fortified foods is
generally limited to the middle- and high-income groups who
are not always at greatest risk of micronutrient deficiencies.
Key factors in the selection of the right food vehicle include
that the vehicle must be consumed regularly and in predictable
amounts, and must be affordable by the target population; it
must be processed in large central mills so that quality control
can be effectively implemented; the fortified food does not
undergo changes in color, taste, or appearance as a result of the
addition of these micronutrients; and the stability and bio-
availability of the micronutrients added to the food must
remain high under standard local conditions of storage and use
(2,35). Present study results are based on several assumptions
that should be accounted for before iron fortification programs
can be implemented on a large-scale. Furthermore, the present
analysis is based on the use of electrolytic iron as fortificant,
but there is no consensus in the scientific community whether
this is indeed the best option (24). Other fortificants have
been suggested, such as ferrous fumarate or ferrous sulfate,
which are more costly but also more bioavailable (24).
In settings where people’s diets are not based around cereal
flours or another convenient food vehicle, supplementation is
still a cost-effective option. Indeed, in areas with a high
prevalence of IDA, it would be very cost effective to spend the
higher amounts on supplementation to achieve greater popu-
lation benefits. It is less cost-effective to apply this option in
areas where the burden from IDA is relatively low. Since the
cost-effectiveness of switching from fortification to supplemen-
tation is below 3  GDP per capita, it falls into the band of
cost-effective interventions.
The analysis used several conservative assumptions to model
the population health effects and costs of iron-deficiency control.
The cost-effectiveness ratios thus obtained can also be interpreted
as conservative estimates. First, the impact of iron-deficiency
control programs on maternal and perinatal mortality were de-
rived from the attributable burden of iron deficiency, as reported
by Stoltzfus et al. (5). Their estimates are based on predicted shifts
of the hemoglobin level that are somewhat lower than the aver-
age hemoglobin level response of pregnant women to iron sup-
plementation in the trials summarized by Sloan et al. (36) [the
latter reported shifts of 8.5–11.7 g/L, whereas Stoltzfus et al. (5)
estimated shifts of 6.5 g/L in AfrD]. Consequently, resulting
reductions in maternal and perinatal mortality rates can be con-
sidered to be conservative estimates. Second, recent studies have
shown that the recommended daily intake of 60 mg is greatly in
excess of the actual requirement for replenishing pregnant
women with iron deficiency in very deficient populations (37).
This would mean that iron supplementation could be provided at
less cost if the period of the regimen is shortened or the quantity
of drugs is reduced. Third, patient adherence to iron supplemen-
tation was assumed to be 67% in this analysis. This is a conser-
vative assumption, considering that adherence values previously
reported range from 55 to 96%, with the median in the higher
end of these values (23). Fourth, while many other groups in the
population are likely to benefit from iron fortification, the disease
model only considered the impact of iron fortification on preg-
nant women. IDA in pregnant women probably accounts for
95% of total deaths averted from fortification, but some deaths
in the rest of the population are also likely to be averted. Fifth,
the analysis reported upon in this paper is based on the impact of
interventions to prevent maternal and perinatal mortality only,
and did not include the gains related to the impact of interven-
tions on intellectual and mental development.
On the other hand, the present analysis may have overes-
timated the health gains from iron-deficiency control because
effectiveness estimates of iron supplementation and iron for-
tification programs were based on data stemming from
TABLE 5
Incremental cost-effectiveness of iron deficiency control in selected regions1,2
Intervention AfrD AmrB EurA SearD
Cost-effectiveness I$ per DALY averted
Iron fortification 50–80% dominated dominated dominated 32
Iron fortification 80–95% 20 134 5,573 49
Iron fortification 95% to iron supplementation 50% 86 dominated dominated dominated
Iron supplementation 50–80% dominated dominated dominated 1793
Iron supplementation 80–95% 1054 13495 35,7624 182
1 AfrD, African subregion with very high adult and high child mortality; AmrB, South American subregion with low adult and child mortality; EurA,
the European subregion with low adult and very low child mortality; SearD, Southeast Asian subregion with high rates of adult and child mortality.
2 Incremental ratios are calculated by comparing costs and effects of interventions to their cheaper alternatives.
3 Incremental from iron fortification at 95% to iron supplementation at 80%.
4 Incremental from iron supplementation at 50–95%.
5 Incremental from iron fortification at 95% to iron supplementation at 95%.
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(mainly) small efficacy trials. There remains a significant gap
between the efficacy and the effectiveness of programs at
controlling iron-deficiency programs among pregnant women,
as most large-scale iron supplementation programs have not
been evaluated with respect to impact. Allen and Gillespie
(25) listed the main operational constraints in large-scale
programs: inefficient and irregular supply, procurement and
distribution of supplements; low accessibility and utilization of
antenatal care by pregnant women; inadequate training and
motivation of frontline health workers; inadequate counseling
of mothers; and low compliance of the intended beneficiaries
with the supplementation regimens. Many of these deficien-
cies can be avoided or rectified in supervised clinical trials but,
in the real world, small trail efficacy does not readily translate
into large-scale program effectiveness. Our study results should
be carefully interpreted in the context and are conditional on
the assumption that efficacy gains also translate into effective-
ness gains, although we did adjust for noncompliance and
suboptimal geographic coverage.
In the absence of empirical data, the present study made
several assumptions on the current coverage of iron-deficiency
control interventions and accessibility to fortified food. Also,
in the absence of sound evidence on the effectiveness of iron
fortification, the present study assumed fortification to be 50%
less effective than supplementation. More research is needed
to substantiate this and other model assumptions. However, by
using varying assumptions, uncertainty analyses showed that
cost-effectiveness estimates were robust to variation in the
model parameters. Study conclusions can thus be maintained,
even in the presence of uncertainty about several assumptions.
The results of the analysis are presented at the regional
level, by using regional resource utilization and epidemiolog-
ical patterns. While, epidemiological patterns are generally
homogeneous between countries in a certain region, resource
utilization patterns are expected to vary.
The findings of this study can be used to inform resource
allocation decisions in iron-deficiency control in a wide range
of countries. Policy makers who wish to extrapolate the results
to their own decision-making context should assess whether
quantities and costs of the various inputs are also applicable to
individual settings. They should then make necessary adjust-
ments to these estimates and calculate cost-effectiveness ratios
that are tailored specifically to their individual context. The
models used for the calculation of costs and effects, including
the raw input data, are available at the WHO Web site (21).
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